David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology.  He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF.  Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology.  He received the IEEE Standards Association Conformity Assessment Award in 2022.  In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology.  He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India.  Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, , and speak at the European Parliament in 2010.  He is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology and he also founded Diabetes Technology & Therapeutics.  He has authored over 320 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity.  His h-index is 58.  Dr. Klonoff has been a PI on over 120 clinical trials of diabetes drugs and devices. He was the lead investigator for the first multicenter RCT of an outpatient artificial pancreas product and chair of the SAB for the first FDA-cleared insulin patch pump.  Dr. Klonoff coined the term "diabetes technology" and founded the Diabetes Technology Meeting and the Hospital Diabetes Meeting. He is senior editor of the world’s first three books about diabetes digital health.  He published the first article that in COVID-19 correcting the hyperglycemia of diabetes increases recovery.  Dr. Klonoff has chaired or served on 61 grant review panels: NIH, CDC, NASA, NSF, US Army, NOAA, ADA, JDRF plus agencies in 12 foreign countries.  He is Chair of the Scientific Advisory Board of the TexasA&M/UCLA/FIU/Rice PATHS-UP Engineering Research Center, Dr. Klonoff created the Glycemia Risk Index to describe the quality of glycemia of continuous glucose monitor tracings.  He chaired the first and second CLSI POCT05 Performance Metrics for Continuous Interstitial Glucose Monitoring Panel, and the Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel.  Dr. Klonoff is a graduate of UC Berkeley, where he was elected to Phi Beta Kappa in his junior year, and UCSF Medical School, where he was elected to Alpha Omega Alpha in his junior year.  His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals. He chaired the IEEE 2621 Standards for Wireless Diabetes Device Security Assurance Committee and he chaired DTSec and DTMoSt, the world’s 1^st and 2^nd consensus medical device cybersecurity standards. For this work Dr. Klonoff was featured in an article in Wired Magazine.